Trump said of Azar, who was confirmed by a vote of 55 to 43 on January 24 to replace Tom Price, MD, as Secretary of HHS, “He’s going to get those prescription drug prices way down…it’s going to come rocketing down.”
In yesterday’s swearing-in ceremony for Alex Azar, the new Secretary of HHS, President Donald Trump promised that the price of prescription drugs will plummet under Azar’s leadership.
Trump said of Azar, who was confirmed by a vote of 55 to 43 on January 24 to replace Tom Price, MD, “He’s going to get those prescription drug prices way down…it’s going to come rocketing down.”
Trump pointed to Azar’s time as president of Eli Lilly, which Trump referred to as a “great company” where Azar “did an incredible job,” as evidence of Azar’s know-how in driving down the high cost of drugs. “We have to get the prices of prescription drugs way down, and unravel the tangled web of special interests that are driving prices up for medicine…you look at other countries, they pay a fraction for the exact same drug. The exact same pill in an identical box from the same factory costs us…many times more…nobody knows that process better than Alex.”
Azar, too, has acknowledged the problem of that tangled web’s role in skyrocketing drug prices. The New York Times reports that, at a symposium at the Manhattan Institute, Azar criticized industry for profiting off steadily increasing the list prices of drugs, saying that “All players—wholesalers like McKesson and Cardinal, pharmacies like CVS and Walgreens, pharmacy benefit managers like Express Scripts and CVS Caremark, and drug companies—make more money when list prices increase.” He added that “The unfortunate victims of these trends are patients.”
Yet some lawmakers have questioned Azar’s commitment to seeing list prices reduced. During the confirmation process, Kaiser Health News reports, Democratic senators, including Ron Wyden of Oregon, pointed out that drug prices rose at Eli Lilly under Azar’s leadership and that Azar had never authorized a decrease in a drug’s price during his time as a pharmaceutical executive.
Under questioning from Senator Debbie Stabenow, D-Michigan, Azar returned to the theme of external interests playing a key role in keeping list prices high, saying of the price hikes at Eli Lilly, “This is what is so bizarre about the way the system is organized. Those price increases happen—and my former employer has said this publicly—during that same period, the net realized price by the company stayed flat…just to cover for increased rebates."
Azar has not yet outlined a plan to address high list prices, although the government's negotiating prices for Medicare appears to be off the table. While Trump has endorsed the idea—saying, “We're the largest buyer of drugs in the world, and yet we don't bid properly. We're going to start bidding. We're going to save billions of dollars over a period of time”—Azar has said that, “For the government to negotiate there, we would have to have a single national formulary that restricted access to all seniors for medicines. I don’t believe we want to go there in restricting patient access.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.